Call us: 1-808-440-4426

1585 Kapiolani Boulevard, Suite 1500 , Honolulu, Hawaii 96814

GPIJ photo 1
If you’ve been diagnosed with cardiovascular disease or have cardiovascular risk factors and you are living with obesity or are overweight, the SURMOUNT-MMO Study may provide a potential treatment option and a healthy lifestyle plan.

The SURMOUNT-MMO Study is evaluating the effectiveness of an investigational medication (trial treatment) on reducing health risks that are commonly found in people who are living with obesity or are overweight. This clinical trial is focusing particularly on cardiovascular (heart) disease and other heart health risks.

Participants will be selected at random to receive either the trial treatment or a placebo, which looks like the trial treatment but does not contain active ingredients. To ensure the most accurate results, neither the participant nor the trial doctor will know which trial treatment they’ve been assigned.
The assigned trial treatment will be administered as a weekly injection, which will be done at home by the participant or a caregiver. Participants and caregivers will receive training on how to administer the injections during an appointment at the beginning of the trial.

The length of participation in the SURMOUNT-MMO Study will vary from person to person but may last up to five years or more, depending on how well the trial treatment is working. The trial schedule includes the following:
• Screening Period: four weeks (one visit)
• Dose Escalation Period: 24 weeks
• Maintenance Treatment Period: up to five years or longer (28+ regular visits; this duration depends on when the specific number of endpoint events for the final analysis occurs)
• Extended Maintenance (EMV) Period: every 12 weeks until the trial ends and the final visit occurs

During the treatment period, there may be an option to complete some visits remotely, at the direction and approval of the trial doctor.

Who May Qualify
Before interested individuals can join this clinical trial, they must be evaluated during the screening period. In order to participate, eligible participants must:
• Be at least 40 years of age
• Have a BMI of 27 kg/m2 or higher
• Have either established cardiovascular disease or
cardiovascular risk factors
• NOT have type 1 or type 2 diabetes

To learn more, sign up or contact:

Ron Ruhaak, Clinical Research Manager